Skip to main content
Clinical Trials/NCT01119716
NCT01119716
Completed
Not Applicable

International Registry on Cardioversion of Atrial Fibrillation

Merck Sharp & Dohme LLC0 sites4,658 target enrollmentMay 25, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Merck Sharp & Dohme LLC
Enrollment
4658
Primary Endpoint
Clinical Type of Atrial Fibrillation at Baseline (Admission)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study will create a prospective registry of consecutive patients with Atrial Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of Afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.

Registry
clinicaltrials.gov
Start Date
May 25, 2010
End Date
February 15, 2013
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participant with documented atrial fibrillation (confirmed by electrocardiogram) in the hospital setting at the time of enrollment
  • Planned cardioversion (of atrial fibrillation)

Exclusion Criteria

  • Already enrolled in this or any other clinical trial
  • Atrial flutter

Outcomes

Primary Outcomes

Clinical Type of Atrial Fibrillation at Baseline (Admission)

Time Frame: Baseline (time of admission)

Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion

Time Frame: At time of treatment (up to 1 day from admission)

Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered.

Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)

Time Frame: Baseline (time of admission)

Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation

Time Frame: up to 60 days from day of treatment (cardioversion)

Treatments Utilized for Participants for Atrial Fibrillation

Time Frame: At time of Treatment (up to 1 day from admission)

Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)

Time Frame: Baseline (time of admission)

Similar Trials